A $3,000 monthly passive income, or $36,000 a year, would be life-changing for most investors.

Certainly, I can think of numerous ways I could use that extra cash in retirement. Some of these would be useful, and others would be just a tad extravagant.

I’m sure you have your own ideas of what you might do with a spare $3,000 a month in passive income.

With that in mind, we’ll look at three top S&P/ASX 300 Index (ASX: XKO) dividend shares you may want to consider buying today to secure that kind of payout.

Before we dive into those, though, please keep in mind that the yields you generally see quoted are trailing yields. Future yields may be higher or lower, depending on a range of company-specific and macroeconomic factors.

Also bear in mind that a well-diversified passive income portfolio should contain more than just three dividend stocks. Investing in a wider basket of companies that operate in different sectors and locations will help to lower the overall risk of your ASX dividend portfolio.

With that said…

Three ASX 300 dividend shares for passive income

The first ASX 300 share I’d buy now to secure my $3,000 in monthly passive income is bank stock Australia and New Zealand Banking Group Ltd (ASX: ANZ).

ANZ paid a partly franked final dividend of 94 cents per share on 22 December. The big four bank will pay the interim dividend of 83 cents per share on 1 July. (ANZ traded ex-dividend on 13 May, so it’s a bit too late to grab that one!)

All told, that equates to a full-year payout of $1.77 a share.

At yesterday’s closing price of $28.43, ANZ shares trade on a partly franked trailing yield of 6.23%.

The second ASX 300 share I’d buy now for passive income is mining stock Fortescue Metals Group Ltd (ASX: FMG).

The iron ore miner paid a fully franked final dividend of $1.00 a share on 28 September. The interim dividend of $1.08 a share was paid on 27 March.

That works out to a 12-month payout of $2.08 a share.

At yesterday’s closing price of $26.51, that equates to a fully franked trailing yield of 7.85%.

Which brings us to the third share I’d buy now for my $3,000 monthly passive income stream, Telstra Group Ltd (ASX: TLS).

Australia’s biggest telco paid a fully franked final dividend of 8.5 cents a share on 30 August. Telstra delivered the interim dividend of 9 cents per share on 28 March. That brings the 12-month payout of 17.5 cents a share.

At yesterday’s closing price of $3.53 a share, Telstra shares trade on a fully franked trailing yield of 4.96%.

To the maths!

Assuming I buy an equal number of shares in each ASX 300 dividend stock, I can expect to earn a yield of 6.3%, largely franked.

To earn my $3,000 monthly passive income, or $36,000 a year, I’d need to invest $568,421 today.

Now that’s a sizeable amount to invest in one go.

But that’s OK.

Investing is a long game.

I can also make regular smaller investments. And by tapping into the magic of compounding, I’ll reach my passive income goal in good time.

The post 3 top ASX 300 dividend shares to buy now for $3,000 a month in passive income appeared first on The Motley Fool Australia.

More reading

• Here’s the new Telstra dividend forecast through to 2026
• Joining the revolution: How I’d invest in ASX AI shares right now
• Beat the bank! 2 ASX stocks worth buying to make more money than interest on savings
• Are CBA share buyers getting the highest growth in return for being the most expensive?
• With a dividend yield over 7%, are Telstra shares a buy for income?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Qantas Airways Limited (ASX: QAN) stock has risen around 20% since the end of February 2024, as shown on the chart below. The ASX travel share has had a rough 12 months, but the future looks more positive.

The company has made some moves in the last few months to win back the trust of passengers after its ticket-selling misdemeanours. For example, Qantas recently expanded its frequent flyer program by adding 20 million more reward seats.

There are (at least) three things that investors should know about Qantas stock, which could make it a compelling investment.

Qantas loyalty division is highly profitable

Many people may think that flights are the only important part of the business. The Qantas loyalty division is becoming increasingly profitable and a bigger contributor to the company’s overall earnings.

In the first half of FY24, Qantas made a total underlying profit before tax of $1.25 billion, down 13%.

It made HY24 underlying earnings before interest and tax (EBIT) in the Qantas domestic division of $641 million, $322 million of underlying EBIT in Qantas international (including freight), $325 million of underlying EBIT in Jetstar Group and $270 million of underlying EBIT in the Qantas Loyalty division. The HY24 Qantas Loyalty underlying EBIT rose by 23% year over year.

Qantas aims to reach $800 million to $1 billion of underlying EBIT by FY30. This segment could contribute to the ASX travel share’s overall profitability at a greater level in the coming years.

Share buyback

A share buyback is one of the most useful things a company can do to increase the value of shares for shareholders.

The ASX travel share announced in the HY24 result that it was increasing its on-market share buyback by up to $400 million.

Buying back shares means the company’s value is being shared between a smaller number of shares, increasing the underlying value in per-share terms. This helps shareholder-related metrics such as the return on equity (ROE) and earnings per share (EPS). In theory, it should help push the Qantas stock price higher as the share buyback continues.

Very cheap valuation

Airlines usually don’t trade on a high price/earnings (P/E) ratio, but the profit they make is just as valuable as the profit dollars made by an ASX tech share, ASX retail share or ASX bank share.

In the FY24 first-half result, the business made statutory net profit after tax (NPAT) of $869 million, or statutory EPS of 52 cents.

The broker UBS has estimated Qantas could generate EPS of 91 cents in FY24, 99 cents in FY27 and $1.11 in FY28. According to those projections, the Qantas stock price is valued at 6.7x FY24’s estimated earnings, 6.2x FY27’s estimated earnings and 5.5x FY28’s estimated earnings.

In three years from now, Qantas’ profit could be substantially higher, so it looks to me to be at a very appealing level now.

The post 3 things about Qantas stock every smart investor knows appeared first on The Motley Fool Australia.

More reading

• 4 super ASX 200 blue chip shares to buy
• How much could a $10,000 investment in Qantas shares be worth in 12 months?
• Here are the top 10 ASX 200 shares today
• Is this why Qantas shares are racing ahead of the ASX 200 on Tuesday?
• 2 cheap ASX 200 shares I’d buy in May

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX biotech shares have been showing significant signs of momentum lately. Exciting clinical trial results and strong investor interest are propelling the sector forward. Plenty of upcoming catalysts and company-specific developments could mean the rest of 2024 is also busy for ASX biotech stocks. 

The biotechnology industry combines biology with technology to develop products for various applications. Biotech stocks are shares in companies developing biotech products, which could have medical, agricultural, or industrial applications. 

Many biotech firms focus on genetics and molecular biology to innovate. Extensive research and development (R&D) is undertaken to create new therapies and technologies. This means substantial R&D spending generally precedes revenue generation. Success in biotech can lead to significant rewards, however, with share values potentially soaring following technological breakthroughs or drug approvals. 

Risks and rewards 

The biotech sector is known for its volatility, driven by the high stakes of clinical trials. The performance of biotech shares tends to be driven by company-specific developments, such as trial data, rather than broader economic factors. This means the sector is generally non-cyclical and can provide potential diversification benefits. 

The ASX is home to a number of groundbreaking biotech companies pioneering innovative therapies. For example, Telix Pharmaceuticals Ltd (ASX: TLX) develops radiopharmaceutical diagnostic agents and therapeutic products that are reshaping oncological care. Fellow ASX 300 biotech Clinuvel Pharmaceuticals Limited (ASX: CUV) develops treatments for serious skin disorders. Both Clinuvel and Telix have successfully commercialised products and are expanding their market presence. This should bode well for future revenue streams. 

The ASX also hosts an array of emerging biotech firms that are beginning to make their mark. Botanix Pharmaceuticals Ltd (ASX: BOT) develops dermatological products and drug treatments. The company is preparing for the upcoming commercial launch of a topical treatment for underarm sweating. Federal Drug Administration (FDA) approval for the treatment is expected by late June 2024. 

Meanwhile, Neuren Pharmaceuticals Ltd (ASX: NEU) is focused on developing treatments for severe neurodevelopmental disorders like Rett syndrome and Fragile X syndrome. It recently achieved FDA approval for a drug that treats Rett syndrome in adults and children over two years old. This is the first and only approved treatment for this condition. Another Neuren Pharmaceuticals drug candidate is also in trials for the treatment of several other disorders. 

As these companies progress through regulatory pipelines and reach commercial stages, the impact on their valuations could be transformative.  

What does the future hold for ASX biotech shares? 

Biotech firms on the ASX are benefitting from global trends that favour advancements in medical technology and increased healthcare demand. The performance of individual biotech companies, however, is ultimately dependent on successful outcomes from R&D activities.
 
Investing in this sector comes with high volatility and risk, but does offer substantial growth potential. Current trends suggest a positive trajectory for ASX biotech shares, making them an interesting sector for investors looking for exposure to innovative healthcare solutions.

The post Which ASX biotech shares are pioneering the future of medicine? appeared first on The Motley Fool Australia.

More reading

• This ASX 200 stock can rocket to a record high: Broker
• 5 things to watch on the ASX 200 on Tuesday
• Here are the top 10 ASX 200 shares today
• Why Cettire, Lendlease, Neuren, and Sayona Mining shares are racing higher today
• Guess which ASX 200 healthcare share just rocketed 11% on ‘groundbreaking trial’

Motley Fool contributor Katherine O’Brien has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The ASX tech stock Siteminder Ltd (ASX: SDR) is a leading opportunity according to one of the top brokers in Australia.

The company aims to provide software that “unlocks the full revenue potential of hotels”. It’s responsible for more than 115 million reservations worth over $70 billion in revenue for its hotel customers annually. Its all-in-one hotel management software for small accommodation providers is called Little Hotelier.

There are a number of positives about the company, according to the broker UBS.

Bullish reasons UBS likes this ASX tech stock

The broker said there are multiple positives for the company’s outlook following the FY24 third-quarter update.

First, UBS noted that Siteminder’s underlying free cash flow of negative $0.2 million was close to breakeven. This was consistent with the management’s target of generating positive free cash flow in the second half of FY24.

The second positive was developments with its new product – ‘Channel Plus’ signed an agreement with Trip.com Group. This means hoteliers can “effortlessly distribute their inventory to the rebounding Chinese outbound tourism market, while Trip.com will gain access to more hotels.” UBS noted that 14 channels have been signed, compared to just six in the FY24 first half. There is “strong initial customer interest” in Siteminder’s new releases, according to UBS.

The third positive about Siteminder is its product enhancements. The ASX tech share has introduced Siteminder Pay into “new markets”. The company also noted the rollout of Siteminder Pay terminals is on track for the first half of FY25. Little Hotelier Autopay, which was released at the start of the FY24 third quarter, has seen “strong adoption and increased Siteminder’s capture of gross booking value at participating properties.”

The final positive UBS pointed to about the ASX tech stock was that hotel subscriber additions have continued the momentum from the first half of FY24, which is “skewed towards larger properties”, with the highest room count per hotel added since the COVID-19 reopening. In the broker’s view, this provides higher revenue per subscriber, a larger base for future transactions and higher new product uptake, combined with lower subscriber churn.

The ASX tech stock is still targeting medium-term revenue growth of 30%. UBS thinks the core offering looks “appealing” and sees potential upside to its estimates if traction for the new product launch is stronger than expected.

Siteminder share price target

UBS has a price target of $6.65 on Siteminder shares, which is currently around 25% higher than it is today. A price target is where the broker thinks the Siteminder share price will be in 12 months.

That positive outlook is despite the Siteminder share price rising around 70% over the past 12 months, as seen on the chart below.

The post The little-known ASX tech stock that could rise 25% in a year appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended SiteMinder. The Motley Fool Australia has positions in and has recommended SiteMinder. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you’re looking for big returns, then it could be worth checking out the small side of the market.

That’s because in exchange for higher risk, investors have the potential for higher rewards.

For example, the small cap ASX share in this article has been tipped to provide investors with a return that is more than double the historic market return.

Let’s see what analysts at Bell Potter are saying about this small cap.

Which small cap ASX share is a buy?

According to a note out of Bell Potter, following a change of analyst, the broker has reaffirmed its buy rating and 29 cents price target on Capitol Health Ltd (ASX: CAJ) shares.

Based on its current share price of 24.5 cents, this implies potential upside of 18% for investors over the next 12 months.

In addition, the broker is expecting the medical imaging company to pay fully franked dividends of 1 cent per share in FY 2024, FY 2025, and FY 2026. This will mean dividend yields of 4.1% each year, boosting the total potential return to over 22%.

To put that into context, a $10,000 would be worth approximately $12,200 in 12 months if Bell Potter’s recommendation proves accurate.

It is also more than double the historical return of the share market, which sits at around 10% per annum.

Why is it bullish?

The note reveals that Bell Potter has boosted its revenue estimates for the coming years. This is to reflect the normalising of volumes and pricing growth rates. And while the broker expects inflationary pressures to weigh on margins in the near term, it appears to believe that this is more than priced into the small cap ASX share’s valuation at present. It commented:

On the transfer of coverage, we have reviewed our earnings estimates. Across FY24e – FY26e, we have increased our revenue estimates by c.1.6% / c.4.7% / c.7.9% driven by normalising volume and pricing growth rates across DI Services and Benefits. However, we expect inflationary pressures to dampen the recovery in operating margins and a lower plateau than previous estimates with margins levelling out at c.22% by FY28e.

This leads to a cut in earnings expectations of c.-8% / c-4.8% / c.- 13.4%. We have upgraded our blended DCF / EV / EBITDA valuation by c.3.6% to $0.29 / sh, reflecting adjustments in our valuation parameters. Catalysts for the share price include continued positive momentum in the Medicare data and M&A activity.

The post Buy this cheap small cap ASX share for a very big return appeared first on The Motley Fool Australia.

More reading

• 3 top ASX 300 dividend shares to buy now for $3,000 a month in passive income
• 3 things about Qantas stock every smart investor knows
• Which ASX biotech shares are pioneering the future of medicine?
• The little-known ASX tech stock that could rise 25% in a year
• ASX investors may choose supermarkets over Wesfarmers shares after ACCC inquiry: broker

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Wesfarmers Ltd (ASX: WES) shares have had an impressive run of share price growth over the past year.

Yesterday, the market’s biggest consumer discretionary share closed at $64.61, up 1.24% for the day, and up 31.7% over the past 12 months.

After such a strong run, top broker Goldman Sachs reckons Wesfarmers shares may lose some investor support to ASX supermarket shares, given their attractive valuations these days.

Wesfarmers shares downgraded by top broker

On Friday, Goldman Sachs downgraded Wesfarmers shares from a buy rating, which it assigned to the stock on 25 January, to a neutral rating.

The 12-month price target remains unchanged at $68.80.

Analysts Lisa Deng and James Leigh explained that their earnings expectations for the conglomerate have not changed, but their buy thesis has now “played out”.

They also commented that Wesfarmers shares may lose some support from investors in favour of fallen ASX supermarket shares amid the Australian Competition and Consumer Commission (ACCC) inquiry.

The ACCC inquiry is examining supermarkets’ pricing practices and the relationship between wholesale, including farmgate, and retail prices. Essentially, it seeks to determine whether supermarkets are price-gouging customers. An interim report is due by 31 August, and a final report is due by 28 February 2025.

What’s happening with ASX supermarket shares?

The two major supermarket shares on the ASX are Woolworths Group Ltd (ASX: WOW) and Coles Group Ltd (ASX: COL).

There’s also ASX mid-cap stock Metcash Ltd (ASX: MTS), which owns the IGA and Foodland grocery store networks, the Cellarbrations, Porters Liquor and Bottle-O liquor brands, and the Mitre 10 chain.

While Deng and Leigh do not name specific supermarket stocks, they point out that they are trading at historically attractive prices.

The analysts said:

As the supermarket ACCC inquiry concludes, we expect the regulatory overhang on supermarkets to dissipate, potentially drawing capital away from WES given the supermarkets’ more attractive valuation.

What’s the P/E comparison to Wesfarmers shares?

According to CBA data, Wesfarmers shares are trading on a price-to-earnings (P/E) ratio of 28.7x.

This compares to Woolworths shares at 22.1x, Coles shares at 20.17x, and Metcash shares at 13.85x.

Over the past 12 months, Woolworths shares have fallen 17.67% to close at $31.46 yesterday. Goldman Sachs has a buy rating on Woolworths shares with a 12-month price target of $39.40.

Coles shares have fallen 10.32% to $16.34. The broker has a neutral rating and a price target of $16.30 on the stock.

Metcash shares have gained 4.66% in value over the past year and closed at $3.82 apiece yesterday. Goldman has a neutral rating on Metcash shares with a price target of $3.70.

As mentioned earlier, Wesfarmers shares have gained 31.7% over the past 12 months.

Other inquiries into the supermarkets

Apart from the ACCC inquiry, others have also taken place concurrently.

A Senate Select Committee on Supermarket Prices handed down its report earlier this month.

Its recommendations included creating divestiture powers in the supermarket sector and giving the ACCC the authority to investigate and prosecute unfair trading practices.

Meantime, a formal review of the Food and Grocery Code of Conduct is also underway.

The code’s purpose is “to address harmful practices in the grocery sector stemming from an imbalance of bargaining power between supermarkets and their suppliers”.

A final report is due on 30 June.

The post ASX investors may choose supermarkets over Wesfarmers shares after ACCC inquiry: broker appeared first on The Motley Fool Australia.

More reading

• 2 cheap ASX dividend shares I’d buy in retirement
• Leading brokers name 3 ASX shares to buy today
• Analysts say these 4 ASX dividend shares are buys
• Why the Woolworths share price now offers a ‘very rare opportunity’
• Why did Goldman Sachs just downgrade Wesfarmers shares?

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Wesfarmers. The Motley Fool Australia has positions in and has recommended Coles Group and Wesfarmers. The Motley Fool Australia has recommended Metcash. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Only a small group of ASX shares have the accolade of increasing their dividend every year for the past decade. This is because it can be challenging to grow the payout annually, as profit can dramatically change from year to year due to trading conditions or shifts in commodity prices.

Businesses operating in resilient industries are the ones that grow profit quite consistently. That’s important because it’s profit generation that funds dividend payments. The below ASX shares are among the leading stocks for regular dividend growth, though dividend hikes are not guaranteed.

Washington H. Soul Pattinson and Co. Ltd (ASX: SOL)

Soul Pattinson has the best record on the ASX when it comes to consecutive dividend increases. Its annual ordinary dividend has grown every year since 2000. The business has paid a dividend every year since 2000.

It has achieved this by owning a portfolio of assets that generate defensive or uncorrelated cash flows, such as telecommunications, resources, swimming schools, property and electrification.

TPG Telecom Ltd (ASX: TPG), Brickworks Limited (ASX: BKW), New Hope Corporation Ltd (ASX: NHC), Macquarie Group Ltd (ASX: MQG), Wesfarmers Ltd (ASX: WES) and BHP Group Ltd (ASX: BHP) are some of Soul Patts’ biggest ASX holdings.

The ASX share currently offers a grossed-up dividend yield of just over 4%.

APA Group (ASX: APA)

APA owns a large portfolio of gas pipelines around the country, transporting half of the country’s gas usage. It also owns gas storage, gas processing, gas-powered energy generation, electricity transmission assets, and renewable energy generation (solar and wind) assets.

The business has grown its payout yearly since 2004, so it has had two consecutive decades of growth.

APA’s cash flow pays for the distribution, which has steadily increased as the business completes more energy projects. A large majority (over 90%) of its revenue is linked to inflation and has seen elevated growth in the last couple of years.

The Australian federal government has confirmed that gas will continue to contribute to Australia’s energy mix for decades to come.

APA has guided it expects to pay a distribution per security of 56 cents in FY24, which is a forward distribution yield of 6.5%.

Sonic Healthcare Ltd (ASX: SHL)

Sonic is one of the world’s leading pathology businesses, with a presence in several countries including Australia, the US, Germany and the UK.

It has increased its dividend every year since 2013 and it has grown its dividend almost every year in the last three decades, with only a few years during that period when the dividend was maintained.

The ASX share has a stated “progressive dividend policy”, where the board aims to increase the payout for shareholders. The last two dividends amount to a dividend yield of 4.3%, excluding franking credits.

Inflation may be hurting Sonic’s short-term profitability, but the company is hopeful for the future, with its investments in artificial intelligence (AI) a key focus.

The post 3 ASX shares with a long history of increasing dividends appeared first on The Motley Fool Australia.

More reading

• If I had to own only one ASX 200 share forever, this would be it
• 2 of the best ASX 200 blue chip shares that money can buy
• These ASX dividend shares offer 6%+ yields right now
• Here are the top 10 ASX 200 shares today
• Why these 4 ASX 200 shares just got downgraded by top brokers

Motley Fool contributor Tristan Harrison has positions in Brickworks, Sonic Healthcare, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Brickworks, Macquarie Group, Washington H. Soul Pattinson and Company Limited, and Wesfarmers. The Motley Fool Australia has positions in and has recommended Apa Group, Brickworks, Macquarie Group, Washington H. Soul Pattinson and Company Limited, and Wesfarmers. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

There are a lot of ASX stocks to choose from on the Australian share market.

But not all are buys at current levels. In fact, some could even be sells. But which ones are buys and which ones are sells?

Let’s take a look at one ASX stock that could be a buy and one that could be a sell according to analysts at Goldman Sachs.

The ASX stock to buy

The first stock we’re going to look at is cloud accounting platform provider Xero Ltd (ASX: XRO).

It impressed the market last week when it released its FY 2024 results and delivered revenue and profit growth ahead of expectations.

The good news is that analysts at Goldman Sachs believe there’s still a significant growth runway ahead for Xero. It highlights that the company currently has a touch under 4.2 million subscribers from an addressable market of over 100 million. The broker commented:

We see Xero as very well-placed to take advantage of the digitisation of SMBs globally, driven by compelling efficiency benefits and regulatory tailwinds, with >100mn SMBs worldwide representing a >NZ$100bn TAM. Given the company’s pivot to profitable growth and corresponding faster earnings ramp, we see an attractive entry point into a global growth story with Xero our preferred large-cap technology name in ANZ – the stock is Buy rated.

Goldman has a conviction buy rating and $164.00 price target on its shares. This implies potential upside of 22% for investors from current levels.

The ASX stock to sell

An ASX stock to sell according to analysts at Goldman Sachs is Commonwealth Bank of Australia (ASX: CBA).

The broker believes that Australia’s largest bank’s shares are severely overvalued at current levels and could be destined to fall materially. It commented:

We are Sell-rated on CBA given: While CBA’s volume momentum in housing lending has improved and BDDs charges remain benign, we don’t think this justifies the extent of CBA’s valuation premium to peers. Coupled with i) a business mix that leaves it more exposed to the current competitive environment, and ii) while CBA has historically done a good job in balancing investment and productivity, we do not think it can escape elevated FY24E cost pressures given heightened inflation.

Goldman currently has a sell rating and $82.61 price target on the ASX stock. Based on its current share price of $120.10, this implies potential downside of 31% for investors over the next 12 months.

The post One ASX stock to buy and one to sell appeared first on The Motley Fool Australia.

More reading

• Are CBA share buyers getting the highest growth in return for being the most expensive?
• 2 no-brainer ASX 200 shares to buy next week
• Here’s how the ASX 200 market sectors stacked up last week
• Top brokers name 3 ASX shares to buy next week
• Hoping to retire? I’d buy these ASX 200 dividend shares for passive income

Motley Fool contributor James Mickleboro has positions in Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price was in fine form on Monday.

The ASX 200 pharma stock ended the day almost 16% higher at $23.97.

This means that Neuren Pharmaceuticals’ shares are now up 78% since this time last year.

It also means that they are now trading within sight of their record high of $25.95.

But if you thought the gains were over, think again. That’s because the team at Bell Potter believes that this ASX 200 stock can rocket to a new record high.

What is the broker saying about this ASX 200 stock?

Bell Potter was pleased with the top-line results from Neuren Pharmaceuticals’ phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Those results revealed that NNZ-2591  delivered a “statistically significant improvement” across all four efficacy measures.

The ASX 200 stock’s CEO, Jon Pilcher, commented: “We are very excited about the results of this first clinical trial in Pitt Hopkins patients. This underserved community has such urgent unmet need and we can now continue towards our goal of developing a first approved treatment.”

Commenting on the results, Bell Potter said:

Another favourable mean CGI-I score of 2.6, albeit from a small sample size of 11 subjects. Anything under 3.5 would’ve been positive (lower=better), hence clearly a good result in our view. We are again impressed to see nearly half (=5/11) of subjects achieving a CGI-I score of 1 or 2, meaning the clinical investigator deemed their symptoms were “very much” or “much” improved from baseline. These larger responses after 13 weeks’ treatment are less likely to be due to a placebo effect in our view. As a comparison, in the trofinetide Phase 3 trial, only 5% on placebo and 13% on trofinetide achieved a CGI-I score of 1 or 2, versus 45% in today’s data.

Big returns ahead

In response to the trial results, the broker has retained its buy rating with an improved price target of $28.00.

Based on the current Neuren Pharmaceuticals share price of $23.97, this implies potential upside of 17% for investors over the next 12 months. It would also mean a new record high for its shares.

The broker concludes:

Following today’s further clinical validation of NNZ-2591 we increase our PT by 6% to $28.00 and maintain our BUY recommendation. Roughly half of our PT is comprised of value ascribed to NNZ-2591, which has now shown encouraging clinical data in two indications, each of which represent a similar if not larger market opportunity than Rett syndrome. For both completed Phase 2 indications, no approved treatments are available and NNZ-2591 is comfortably in poll position to be the first drug to market. A third Phase 2 readout with NNZ-2591 in Angelman syndrome is expected in Q3 CY24.

The post This ASX 200 stock can rocket to a record high: Broker appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Tuesday
• Here are the top 10 ASX 200 shares today
• Why Cettire, Lendlease, Neuren, and Sayona Mining shares are racing higher today
• Guess which ASX 200 healthcare share just rocketed 11% on ‘groundbreaking trial’
• ASX 200 healthcare stock up 40% in 6 months halted ahead of major trial results

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you have a high tolerance for risk, then it could be worth thinking about adding the speculative ASX stock in this article to a balanced portfolio.

The stock in question is IperionX Ltd (ASX: IPX).

What is IperionX?

IperionX is aiming to become a leading American titanium metal and critical materials company.

It is using patented metal technologies to produce high performance titanium alloys from titanium minerals or scrap titanium. This is achieved with lower energy, low costs and low carbon emissions.

The company notes that its Titan critical minerals project is the largest JORC-compliant mineral resource of titanium, rare earth, and zircon minerals sands in the United States.

This leaves it well positioned to benefit from demand for titanium metal and critical minerals for advanced U.S. industries. This includes space, aerospace, defence, consumer electronics, hydrogen, electric vehicles, and additive manufacturing.

Why is this a speculative ASX stock to buy?

According to a note out of Bell Potter, its analysts think this ASX stock could be seriously undervalued at current levels.

The note reveals that the broker has reaffirmed its speculative buy rating with an improved price target of $3.85. Based on its current share price of $2.19, this implies potential upside of 76% for investors over the next 12 months.

To put that into context, a $10,000 investment would be worth approximately $17,600 by this time next year if Bell Potter is on the money with its recommendation.

Though, it is worth acknowledging that its speculative rating means that there’s potential for sizeable losses as well. That’s why this ASX stock is likely to be only suitable for investors that have a much higher than average risk tolerance.

What is the broker saying?

Bell Potter believes that the company has the potential to disrupt the titanium supply chain with its technology. It explains:

IPX has the potential to disrupt the incumbent titanium supply chain through materially lowering production costs and manufacturing waste. Large-scale production will commence this year, further de-risking the company’s technologies and enabling IPX to progress commercial relationships with several high-profile aerospace, automotive, luxury goods and government end users.

Our valuation is mostly supported by Phase 2 earnings using relatively conservative assumptions with respect to process margins. There is potential for IPX to rapidly scale Phase 2 and cement itself as a key supplier in the US and global titanium value chains. Our IPX valuation is now $3.85/sh (previously $3.70/sh), having removed the assumption of a near-term equity raise and its corresponding dilution.

All in all, the broker believes IperionX could have a very bright future ahead of it. This could make it one to watch very closely.

The post This disruptive speculative ASX stock could rise 75% in 12 months appeared first on The Motley Fool Australia.

More reading

• These 3 ASX All Ords stocks turned $500 into at least $16,500 in less than a decade!
• Why Fletcher Building, Healius, Iperionx, and Iress shares are sinking today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.